ArticleScientific reports2025
Majusculamide-o, a simplified marine natural product analog, exhibits potent and specific cancer cell cytotoxicity.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Metastatic solid tumors (e.g., ovary, pancreas, liver, lung, and brain) contribute to a high mortality rate in cancer patients with few therapeutically effective anticancer drugs available for their treatment, highlighting the need to develop agents that target solid tumors. Natural products (NPs) derived from cyanobacteria possess potent anticancer activity, yet most are hard to synthesize and modify to improve therapeutic efficacy. Here, we have efficiently synthesized a simplified analog of the marine NP majusculamide D, majusculamide o (maj-o, 1), that has remarkable potency and selective cytotoxicity towards various metastatic cancer cells. We found that maj-o (1) treatment presents potent cytotoxicity in various cancer cell lines of the ovary (OVCAR3), pancreas (PANC1), brain (U251N), and lung (H125) in a dose-dependent manner, with the least cytotoxic effect towards non-metastatic or primary tumors of the liver (HEPG2) and ovary (OVCAR8). 1 significantly alters gene expression signatures with more treatment time and affects pathways associated with PI3K-Akt signaling and the Hippo pathway. Our finding suggests that maj-o has great potential to serve as a lead compound for the development of novel antineoplastics for solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.